Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment
China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...
Cancer
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates
Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...
GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML
Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...
Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials
The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...
AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment
AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Anti-Tumor Drug Candidate SHR-2022
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical...
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million...
GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors
GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...
BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...
Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...
Sichuan Biokin’s IZalontamab Gets US FDA Greenlight for NSCLC Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Innovent Biologics Withdraws Parsaclisib Filing in China, Halts Development
Innovent Biologics Inc., a leading China-based biotech company (HKG: 1801), has announced the voluntary withdrawal...
Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has entered into a licensing agreement with...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...